(51) International Patent Classification 6:
A61K 38/28, 30/00, C07K 7/10

(11) International Publication Number:
WO 99/34822

(43) International Publication Date:
15 July 1999 (15.07.99)

(21) International Application Number:
PCT/US98/00288

(22) International Filing Date:
9 January 1998 (09.01.98)

(71) Applicant: AMYLIN PHARMACEUTICALS, INC. [US/US]; 9373 Towne Centre Drive, San Diego, CA 92121 (US).

(72) Inventors: L’ITALIAN, James; 13292 Norcroft Road, San Diego, CA 92130 (US); MUSUNURI, Shankar; 23 Linwood Drive, Exton, PA 19341 (US); RUBY, Cale; 13187 Sundance Avenue, San Diego, CA 92129 (US).


Published
With international search report.

(54) Title: FORMULATIONS FOR AMYLIN AGONIST PEPTIDES

(57) Abstract

The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5 % (w/v) amylin agonist, preferably pramlintide, in an aqueous system along with approximately 0.02 to about 0.5 % (w/v) of an acetate, phosphate, citrate, or glutamate buffer to a pH of the final composition of approximately 3.0 to about 6.0 as well as approximately 1.0 to 10 % (w/v) of a carbohydrate or polyhydric alcohol tonificator; and, optionally, approximately 0.005 to 1.0 % (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, parabens and phenol. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin in the same syringe for administration to a patient.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL  Albania
AM  Armenia
AT  Austria
AU  Australia
AZ  Azerbaijan
BA  Bosnia and Herzegovina
BB  Barbados
BE  Belgium
BF  Burkina Faso
BG  Bulgaria
BJ  Benin
BR  Brazil
BY  Belarus
CA  Canada
CF  Central African Republic
CG  Congo
CH  Switzerland
CI  Côte d'Ivoire
CM  Cameroon
CN  China
CU  Cuba
CZ  Czech Republic
DE  Germany
DK  Denmark
EE  Estonia
ES  Spain
FI  Finland
FR  France
GA  Gabon
GB  United Kingdom
GE  Georgia
GH  Ghana
GN  Guinea
GR  Greece
HU  Hungary
IE  Ireland
IL  Israel
IS  Iceland
IT  Italy
JP  Japan
KE  Kenya
KG  Kyrgyzstan
KP  Democratic People's Republic of Korea
KR  Republic of Korea
KZ  Kazakhstan
LC  Saint Lucia
LI  Liechtenstein
LK  Sri Lanka
LR  Liberia
LS  Lesotho
LT  Lithuania
LU  Luxembourg
LV  Latvia
MC  Monaco
MD  Republic of Moldova
MG  Madagascar
MK  The former Yugoslav Republic of Macedonia
ML  Mali
MN  Mongolia
MR  Mauritania
MW  Malawi
MX  Mexico
NE  Niger
NL  Netherlands
NO  Norway
NZ  New Zealand
PL  Poland
PT  Portugal
RO  Romania
RU  Russian Federation
SE  Sweden
SG  Singapore
SI  Slovenia
SK  Slovakia
SN  Senegal
SZ  Swaziland
TD  Chad
TG  Togo
TJ  Tajikistan
TM  Turkmenistan
TR  Turkey
TT  Trinidad and Tobago
UA  Ukraine
UG  Uganda
US  United States of America
UZ  Uzbekistan
VN  Viet Nam
YU  Yugoslavia
ZW  Zimbabwe
FORMULATIONS FOR AMYLIN AGONIST PEPTIDES

This application claims the benefit of U.S. Provisional Application No. 60/035,140, filed January 8, 1997, the contents of which are hereby incorporated by reference in their entirety.

FIELD OF INVENTION

This invention relates to pharmaceutical formulations of amylin agonist peptides, preferably in liquid dosage form. Additionally, this invention relates to amylin agonist pharmaceutical formulations which are compatible upon mixing with insulin.

BACKGROUND OF THE INVENTION

Deposition of amyloid in pancreatic islets is a common feature in human Type II diabetic patients. The major protein forming these amyloid particles, called amylin, has a propensity to form fibril amyloid structures. National Academy of Sciences USA 8628, 1987. Amylin is a 37 amino acid protein which, in its fully active form, is carboxy-amidated and has a disulfide bridge between the cysteine residues found at

Therapeutic opportunities for insulin-using and other people with diabetes who are deficient in amylin or for whom amylin therapy would be of benefit, and hormone blockage for other people, for example, the obese and Type II diabetics and those with insulin resistance who may have elevated plasma amylin or undesired amylin activity have been pursued. The use of amylin agonists, including amylin itself, for the treatment of diabetes is described and claimed in U.S. Patent No. 5,175,145. The use of amylin antagonists for the treatment of Type II diabetes mellitus, obesity and essential hypertension, and insulin resistance, are

The most severe form of the disease is Type I (juvenile-onset) diabetes. There are an estimated 1 million Type I diabetics in the U.S. who need daily insulin injections for survival. Their quality of life is often markedly affected by the rigors of their daily metabolic imbalances, in particular hypoglycemic attacks (dangerously low blood glucose) and by the onset of serious long-term complications, including blindness, kidney failure, impotence, ulcers, amputations and atherosclerosis (NIH Diabetes Complications and Control Trial).

Type II (adult-onset) diabetes afflicts over 10 million Americans, who are also subject to the same complications. Impaired glucose tolerance, a risk factor for Type II diabetes and cardiovascular disease, is thought to affect another 20 million people in the U.S. and is not treatable by any known regimen. There is also an alarming increase in the incidence of Type II diabetics in groups of populations around the world, whose standard of living is increasing through economic development or migration. Sulfonylureas are the primary oral antihyperglycemic diabetic medications sold in the
U.S. Discovered in the 1940's, these compounds do not address the underlying causes of Type II diabetes and, in many cases, are not effective or lose their efficacy after a few years of treatment. Type II diabetics do not lack insulin, rather they are insulin resistant, so that insulin does not work properly and the insulin secretory responses are disordered.

After a meal, the pancreas secretes insulin in response to a rise in glucose. Insulin stimulates the uptake of glucose into muscle and fat, and signals the liver to reduce glucose production; this results in a return of blood glucose to normal levels. In muscle, large amounts of glucose are stored as glycogen. Some of the glycogen is broken down into lactate, which circulates to the liver and can be converted back into glucose and stored as glycogen. Between meals the liver breaks down these glycogen stores to provide glucose to the brain and other tissues. This cycle in which glycogen is effectively transferred from muscle to liver is known as the Cori cycle. The stimulus for this flux from muscle to liver under resting conditions remain unidentified; recent results indicate that amylin provides a major stimulus to this pathway.

Amylin has been demonstrated to have direct
metabolic effects in both skeletal muscle and the pancreas. In skeletal muscle, amylin acts as a non-competitive antagonist of insulin, reducing insulin-stimulated incorporation of glucose into glycogen. In vitro studies indicate that amylin reduces glycogen synthase activity and favors the formation of an active form of glycogen phosphorylase, the enzyme that converts glycogen into glucose 6-phosphate. The actions of amylin on skeletal muscle promote glycogen breakdown, thus stimulating lactate formation and increasing turnover of the Cori cycle. Amylin is co-secreted with insulin from pancreatic beta cells and has been demonstrated to suppress insulin secretion. It appears to provide feedback regulation of the beta-cell, in order to modulate insulin secretory activity.

It is believed that amylin plays a role in the regulation of glucose uptake from ingested food into blood, and that amylin or amylin agonist therapy in diabetics, particularly insulin-using diabetics, such as Type I diabetics and late-stage Type II diabetics, will smooth the excessive glucose rises that these patients typically experience after meals. Deficiency of an important hormone such as amylin which has been reported to have effects on carbohydrate, fat and bone
metabolism, may also disrupt other important physiological mechanisms. The co-administration of amylin, or an amylin agonist which exerts the physiological effects of amylin, will significantly improve existing insulin therapy by restoring the appropriate metabolic balance.

Many factors affect the stability of a pharmaceutical product, including the chemical reactivity of the active ingredient(s), the potential interaction between active and inactive ingredients, the manufacturing process, the dosage form, the container-closure system, and the environmental conditions encountered during shipment, storage, handling and length of time between manufacture and usage.

Pharmaceutical product stability is determined by the chemical stability as well as the physical stability of the formulation. Physical factors including heat and light may initiate or accelerate chemical reactions.

Optimal physical stability of a formulation is very important for at least three primary reasons. First, a pharmaceutical product must appear fresh, elegant and professional, when it is administered to a patient. Any changes in physical appearance such as color changes or haziness can cause a patient or consumer to lose
confidence in the product. Second, because some products are dispensed in multiple-dose containers, uniformity of dose content of the active ingredient over time must be assured. A cloudy solution or a broken emulsion can lead to a non-uniform dosage pattern. Third, the active ingredient must be available to the patient throughout the expected shelf life of the preparation. A breakdown of the product to inactive or otherwise undesired forms can lead to non-availability of the medicament to the patient.

Stability of a pharmaceutical product, then, may be defined as the capability of a particular formulation to remain within its physical, chemical, microbiological, therapeutic and toxicological specifications. A stable solution retains its original clarity, color and odor throughout its shelf life. Retention of clarity of a solution is a main concern in maintaining physical stability. Solutions should remain clear over a relatively wide temperature range such as about 4°C to about 37°C. At the lower range an ingredient may precipitate due to a lower solubility at that temperature, while at higher temperatures homogeneity may be destroyed by extractables from the glass containers or rubber closures. Thus, solutions of
active pharmaceutical ingredients must be able to handle cycling temperature conditions. Similarly, a formulation should retain its color throughout this temperature range, and its odor should be stably maintained.

Small peptides are typically unstable and are susceptible to degradation in aqueous solution. In this regard, once a human amylin agonist or amylin has less than approximately 90% of its labeled potency, it is no longer considered to be suitable for administration to a patient. Various types of molecules such as sugars, surfactant, amino acids and fatty acids, used singly or in combination, have been used in efforts to stabilize protein and peptide products against degradation. See Wang and Hanson, *J. Parenteral Science and Technology Supplement*, 1988, Technical Report No. 10 (describing parenteral formulations of proteins and peptides); Manning et al., *6 Pharmaceutical Research*, 1989. Examples of excipients such as buffers, preservatives, isotonic agents, and surfactants are also known in the art. See 21 C.F.R. §180.22 *et seq.* (defining recognized food additives); Wang and Kowal, 34 *J. Parenteral Drug Association* 452, 1980 (describing various excipients); A.R. Gennaro et al., 17th Remington's "Pharmaceutical
Sciences," 1985; Avis et al., Pharmaceutical Dosage Forms: Parenteral Medications, Vol. 1, 1992, all of which, including the definitions of various useful excipients, are hereby incorporated by reference herein.

It is understood that the development of a suitable pharmaceutical formulation for administration to a subject is complex. A need exists in the art for pharmaceutical formulations of amylin agonist peptides, or amylin, designed to provide single or multiple doses having substantial stability when refrigerated and at room temperature. Further, a need exists in the art for a liquid pharmaceutical formulation packaged with a container/closure system that also minimizes the physical and chemical degradation of such peptides.

Finally, a need exists for a liquid pharmaceutical formulation for amylin agonist peptides, or amylin, which can be mixed with insulin prior to administration. The invention described and claimed herein meets these needs.

SUMMARY OF THE INVENTION

The inventors have discovered novel pharmaceutical formulations and dosage forms useful for the administration of amylin agonist peptides to a patient.
in need of treatment with such compounds. These dosage forms include approximately 0.01 to 0.5% (w/v), respectively, of an amylin agonist, or amylin, as the active ingredient in an aqueous system along with approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer to obtain a pH of the final composition of approximately 3.0 to 6.0, as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier in an aqueous continuous phase, provided, however, that if the amylin agonist or amylin has similar physiochemical characteristics similar to those of human amylin, it should be formulated and lyophilized for storage (and used immediately upon reconstitution). Approximately 0.005 to 1.0% (w/v) of an antimicrobial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol is also present in the formulation of product designed to allow the patient to withdraw multiple doses. Importantly, a stabilizer is not required in this amylin agonist product formulation. A sufficient amount of water for injection is used to obtain the desired concentration of solution. Sodium chloride, as well as other excipients, may also be present, if
desired. Such excipients, however, must maintain the overall stability of the amylin agonist or amylin peptide. The liquid formulations of the invention should be substantially isotonic. An isotonic solution may be defined as a solution that has a concentration of electrolytes, non-electrolytes, or a combination of the two that will exert equivalent osmotic pressure as that into which it is being introduced, here, for example in the case of parenteral injection of the formulation, a mammalian tissue. By “substantially isotonic” is meant within ±20% of isotonicity, preferably within ±10%. The formulated product is included within a container, typically, for example, a vial, cartridge, prefilled syringe or disposable pen.

We have found that this novel parenteral dosage form surprisingly maintains the stability of the peptide for up to four years at refrigerated temperatures, e.g., approximately 5°C, and over 30 days at room temperature, e.g., approximately 30°C.

The inventors have further discovered that this pharmaceutical formulation can be further mixed with insulin product in a syringe and retain short term stability. This short term mixing compatibility is extremely advantageous. This allows administration of a
single injection of an amylin agonist, or amylin, along with insulin to a patient.

This invention describes formulations of amylin agonists, or amylin, which are stabilized with respect to aggregation, adsorption and degradation, and thus enhance preservation of their biological activities, although formulations of either an amylin agonist or an amylin which has physicochemical properties similar to those of human amylin, which is poorly soluble and highly unstable should also include a stabilizer, comprising 1.0 to 10% (w/v) of a carbohydrate or a polyhydric alcohol, and a surfactant, preferably about 0.1 to about 1.0% (w/v) of polysorbate 80 or other non-ionic detergent, should be lyophilized promptly after formulation, and must be used promptly upon reconstitution and are therefore less preferred.

A further aspect of the invention features a formulation including an amylin agonist, mixed with a stabilizing compound which reduces loss of biological potency of the peptide in, for example, an amylin specific receptor binding assay, reduces loss of biological activity as measured in, for example, the in vitro soleus muscle bioassay, and general loss of material by, for example, an HPLC assay, as compared to
a formulation consisting of the amylin alone.

In a related aspect, the invention features a method for formulating amylin agonists that retain short term (e.g., 24 hours) mixing compatibility with insulin.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

**BRIEF DESCRIPTION OF THE DRAWINGS**

FIGURE 1 shows the degradation rates of pramlintide at various pH formulations.

FIGURE 2 shows the stability of the pramlintide formulation over time at 30°C.

FIGURE 3 shows the stability of the pramlintide formulation over time at 40°C.

FIGURE 4 shows the stability of the pramlintide formulation over time at 50°C.

FIGURE 5 shows an Arrenhius plot of the $K_{obs}$ values from FIGURES 2-4.

FIGURE 6 shows plasma concentrations versus time for insulin following mixing the amylin agonist peptide pramlintide formulated according to Table A.

**DETAILED DESCRIPTION**

Peptide drugs undergo physical and chemical

**SUBSTITUTE SHEET (RULE 26)**
degradation in solution, and lose their biological activity. The dosage form reported in this invention minimizes the chemical degradation of amylin, for example, pramlintide, through different pathways, for example, deamidation and peptide bond hydrolysis, and keeps the peptide biologically active for up to four years when stored at approximately 5°C. This dosage form is well-tolerated by patients. The container/closure system used to store this formulation also minimizes the physical loss of drug product through adsorption onto the container surface or adsorption into the rubber closure.

People with Type I diabetes must be treated with exogenous insulin. Generally, persons who initially require insulin tend to be younger than 30 years of age at the time of diagnosis, lean, prone to developing ketoacidosis, and markedly hyperglycemic even in the fasting state. Insulin is also indicated for Type II diabetics who do not respond to diet and exercise therapy either alone or in combination with oral hypoglycemic drugs. Insulin therapy is also necessary in some Type II diabetic patients who are subject to stresses such as infections, pregnancy, or surgery. In Type II diabetics, doses of 10-20 units of intermediate-
acting insulins are occasionally needed to bring hyperglycemia under control.

Any functional macromolecular component of a patient may serve operationally as a drug receptor. A particularly important group of drug receptors are proteins that normally serve as receptors for endogenous regulatory ligands (e.g., hormones, neurotransmitters). Many drugs act on such physiological receptors. Those that mimic the effects of the endogenous regulatory compound are termed agonists.

By "amylin agonist" is meant peptide analogues of human amylin useful as agonists of amylin, including but not limited to those amylin agonists which are represented by the formula

\[ ^{1} A_{1} - X - Asn - ^{5} Ala - Thr - Y - Ala - Thr - ^{10} Gln - Arg - Leu - \\
^{2} B_{1} - Asn - ^{15} Phe - Leu - C_{1} - D_{1} - E_{1} - ^{20} F_{1} - G_{1} - Asn - H_{1} - Gly - ^{25} I_{1} - \\
^{3} J_{1} - Leu - K_{1} - L_{1} - ^{30} Thr - M_{1} - Val - Gly - Ser - ^{35} Asn - Thr - Tyr - Z \]

wherein \( A_{1} \) is hydrogen Lys, Ser, Ala, des-\( \alpha \)-amino Lys, or acetylated Lys; \( B_{1} \) is Ala, Ser or Thr; \( C_{1} \) is Val, Leu or Ile; \( D_{1} \) is His or Arg; \( E_{1} \) is Ser or Thr; \( F_{1} \) is Ser, Thr, Gln or Asn; \( G_{1} \) is Asn, Gln or His; \( H_{1} \) is Phe, Leu or Tyr; \( I_{1} \) is Ala or Pro; \( J_{1} \) is Ile, Val, Ala or Leu; \( K_{1} \) is Ser, Pro, Leu, Ile or Thr; \( L_{1} \) is Ser, Pro or Thr; \( M_{1} \) is Asn, Asp or Gln; \( X \) and \( Y \) are independently selected residues.
having side chains which are chemically bonded to each other to form an intramolecular linkage; and Z is hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; provided that (a) when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is His, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Phe, I₁ is Ala, J₁ is Ile, K₁ is Ser, L₁ is Ser, and M₁ is Asn; (b) when A₁ is Lys, B₁ is Ala, C₁ is Ile, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Ala, J₁ is Ile, K₁ is Ser, L₁ is Pro, and M₁ is Asn; (c) when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is Thr, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Ala, J₁ is Ile, K₁ is Ser, L₁ is Pro, and M₁ is Asn; (d) when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Pro, J₁ is Val, K₁ is Pro, L₁ is Pro, and M₁ is Asn; (e) when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is His, E₁ is Ser, F₁ is Asn, G₁ is Asn, H₁ is Leu, I₁ is Pro, J₁ is Val, K₁ is Ser, L₁ is Pro and M₁ is Asn; or (f) when A₁ is Lys, B₁ is Thr, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is His, H₁ is Leu, I₁ is Ala, J₁ is Ala, K₁ is Leu, L₁ is Pro and M₁ is Asp; then one or more of any of A₁ to M₁ is not an L-amino acid and Z is not amino, it being further noted that single-proline substituted peptides at I₁, K₁, and
L₁ are not preferred.

Suitable side chains for X and Y include groups derived from alkyl sulfhydryls which may form disulfide bonds; alkyl acids and alkyl amines which may form cyclic lactams; alkyl aldehydes or alkyl halides and alkylamines which may condense and be reduced to form an alkyl amine bridge; or side chains which may be connected to form an alkyl, alkenyl, alkynyl, ether or thioether bond. Preferred alkyl chains include lower alkyl groups having from about 1 to about 6 carbon atoms.

As used herein, the following terms have the following meanings unless expressly stated to the contrary: The term "alkyl" refers to both straight- and branched-chain alkyl groups. The term "lower alkyl" refers to both straight- and branched-chain alkyl groups having a total of from 1 to 6 carbon atoms and includes primary, secondary and tertiary alkyl groups. Typical lower alkyls include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, n-hexyl, and the like. The term "aryl" refers to carbocyclic aromatic groups of 6 to 14 carbon atoms such as phenyl and naphthyl, as well as heterocyclic aromatic groups containing 1 to 3 heteroatoms (nitrogen, oxygen,
sulfur, etc.) such as pyridyl, triazolopyrazine, pyrimidine and the like. The term "aralkyl" refers to an "aryl" group of 6 to 10 carbon atoms directly attached to an "alkyl" group of 1 to 4 carbon atoms and includes for example benzyl, p-chlorobenzyl, p-methylbenzyl, and 2-phenylethyl. The term "cycloalkyl" refers to cyclic alkyl groups of 5 to 8 carbon atoms.

Biologically active derivatives of the above formula agonist analogues are also included in which the stereochemistry of individual amino acids may be inverted from (L)/S to (D)/R at one or more specific sites. Also included are the agonist analogues modified by glycosylation of Asn, Ser and/or Thr residues.

Biologically active agonist analogues of amylin are included which contain less peptide character. Such peptide mimetics may include, for example, one or more of the following substitutions for -CO-NH- amide bonds:

depsipeptides (-CO-O-), iminomethylene (-CH₂-NH-), trans-alkenes (-CH=CH-), -enaminonitriles (-C(=CH-CN)-NH-), thioamides (-CS-NH-), thiomethylene (-S-CH₂- or -CH₂-S-), methylene (CH₂-CH₂-) and retro-amides (NH-CO-).

Amylin agonist compounds form salts with various inorganic and organic acids and bases. Such salts include salts prepared with organic and inorganic acids,
for example, HCl, HBr, H₂SO₄, H₃PO₄, trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid, toluenesulfonic acid, maleic acid, fumaric acid and camphorsulfonic acid. Salts prepared with bases include, for example, ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkali earth salts (such as calcium and magnesium salts). Acetate, hydrochloride, and trifluoroacetate salts are preferred.

The salts may be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.

Amylin agonist compounds include various stereoisomers. In the preferred compounds of this invention, the chiral centers on the peptide backbone are all S.

Amylin agonists may be prepared by those of ordinary skill in the art, as described in "Amylin Agonist Peptides and Uses Therefor," U.S. Patent No. 5,686,411, the contents of which is hereby incorporated.
by reference in its entirety.

By "human amylin" is meant the 37 amino acid amylin set forth in U.S. Patent No. 5,357,052.

The nomenclature of the compounds of the present invention can be used to indicate both the peptide that the sequence is based on and the modifications made to any basic peptide amylin sequence, such as human amylin. An amino acid preceded by a superscript number indicates that the named amino acid replaces the amino acid normally present at the amino acid position of the superscript in the basic amino acid sequence. For example, "$^{18}$Arg$^{25,28}$Pro-h-amylin" refers to a peptide based on the sequence of "h-amylin" or "human-amylin" having the following substitutions: Arg replacing His at residue 18, Pro replacing Ala at residue 25 and Pro replacing Ser at residue 28. The term "des-$^{1}$Lys-h-amylin" refers to a peptide based on the sequence of human amylin, with the first, or N-terminal, amino acid deleted.

In addition to the description of compounds pursuant to the above formula, certain preferred compounds may be identified, including $^{25,28,29}$Pro-h-amylin, $^{18}$Arg$^{25,28}$Pro-h-amylin, des-$^{1}$Lys$^{18}$Arg$^{25,28}$Pro-h-amylin, des-$^{1}$Lys-h-amylin and $^{25}$Pro$^{26}$Val$^{28,29}$Pro-h-amylin. These
peptides preferably have a reduced tendency to form aggregates or to precipitate under pressure compared to human amylin.

Compounds described herein which are especially preferred include \(^{18}\text{Arg}^{25,28}\text{Pro-h-amylin}, \text{ des-}^{1}\text{Lys}^{18}\text{Arg}^{25,28}\text{Pro-h-amylin}, \text{ des-}^{1}\text{Lys}^{18}\text{Arg}^{25,28,29}\text{Pro-h-amylin}, \text{ des-}^{1}\text{Lys}^{25,28,29}\text{Pro-h-amylin}, \text{ and }^{25,28,29}\text{Pro-h-amylin}.

Still further amylin agonist peptide compounds include:

\[
\begin{align*}
^{23}\text{Leu}^{25,28,29}\text{Pro-h-amylin;} \\
^{23}\text{Leu}^{25,28,29}\text{Val}^{28,29}\text{Pro-h-amylin;} \\
\text{des-}^{1}\text{Lys}^{23}\text{Leu}^{25}\text{Pro}^{28,29}\text{Val}^{28}\text{Pro-h-amylin;} \\
^{18}\text{Arg}^{23}\text{Leu}^{25}\text{Pro}^{28,29}\text{Val}^{28}\text{Pro-h-amylin;} \\
^{18}\text{Arg}^{23}\text{Leu}^{25,28,29}\text{Pro-h-amylin;} \\
^{18}\text{Arg}^{23}\text{Leu}^{25,28,29}\text{Pro-h-amylin;} \\
^{18}\text{Arg}^{23}\text{Leu}^{25,28,29}\text{Pro-h-amylin;} \\
^{17}\text{Ile}^{23}\text{Leu}^{25,28,29}\text{Pro-h-amylin;} \\
^{17}\text{Ile}^{25,28,29}\text{Pro-h-amylin;} \\
\text{des-}^{1}\text{Lys}^{17}\text{Ile}^{23}\text{Leu}^{25,28,29}\text{Pro-h-amylin;} \\
^{17}\text{Ile}^{18}\text{Arg}^{23}\text{Leu-h-amylin;} \\
^{17}\text{Ile}^{18}\text{Arg}^{23}\text{Leu}^{26}\text{Val}^{29}\text{Pro-h-amylin;} \\
^{17}\text{Ile}^{18}\text{Arg}^{23}\text{Leu}^{25,28,29}\text{Pro-h-amylin;} \\
^{13}\text{Thr}^{21}\text{His}^{23}\text{Leu}^{26}\text{Ala}^{28,29}\text{Leu}^{29}\text{Pro}^{31}\text{Asp-h-amylin;} \\
^{13}\text{Thr}^{21}\text{His}^{23}\text{Leu}^{26}\text{Ala}^{28,29}\text{Pro}^{31}\text{Asp-h-amylin;} \\
\text{des-}^{1}\text{Lys}^{13}\text{Thr}^{21}\text{His}^{23}\text{Leu}^{26}\text{Ala}^{28,29}\text{Pro}^{31}\text{Asp-h-amylin;} \\
\end{align*}
\]
1 Thr^{18}Arg^{21}His^{23}Leu^{26}Ala^{29}Pro^{31}Asp-h-amylin;
1 Thr^{18}Arg^{21}His^{23}Leu^{26,29}Pro^{31}Asp-h-amylin; and,
1 Thr^{18}Arg^{21}His^{23}Leu^{25}Pro^{26}Ala^{28,29}Pro^{31}Asp-h-amylin.

Pro-h-amylin which is also referred to as "pramlintide," is a most preferred agonist of human amylin. Pro-h-amylin will be referred to as "pramlintide" hereafter. Pramlintide is substantially different from and better than human amylin, retaining the desired biological properties of human amylin with superior attributes, including superior pharmaceutical properties (L.S.L. Gaeta and T.J. Rink, Medicinal Chemistry Research, 1994). Pramlintide and other amylin agonists set forth herein are described and claimed in United States Patent No. 5,686,411, issued November 11, 1997.

Amylin agonists must be formulated into a stable, safe pharmaceutical composition for administration to a patient. The novel pharmaceutical formulations of the present invention comprise approximately 0.01 to 0.5% (w/v) of an amylin agonist, or amylin, approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer allowing a pH of the final composition of from 3.0 to 6.0; approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonifier and,
optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol. Such a preservative is generally included if the formulated peptide is to be included in a multiple use product. A sufficient amount of water for injection is used to obtain the desired concentration of solution. Additional tonicifying agents such as sodium chloride, as well as other excipients, may also be present, if desired. Such excipients, however, must maintain the overall tonicity of the amylin agonist, or amylin, and are generally not preferred for this formulation except as may be needed.

The terms buffer, buffer solution and buffered solution, when used with reference to hydrogen-ion concentration or pH, refer to the ability of a system, particularly an aqueous solution, to resist a change of pH on adding acid or alkali, or on dilution with a solvent. Characteristic of buffered solutions, which undergo small changes of pH on addition of acid or base, is the presence either of a weak acid and a salt of the weak acid, or a weak base and a salt of the weak base. An example of the former system is acetic acid and sodium acetate. The change of pH is slight as long as
the amount of hydronium or hydroxyl ion added does not exceed the capacity of the buffer system to neutralize it.

The stability of the peptide formulation of the present invention is enhanced by maintaining the pH of the formulation in the range of approximately 3.0 to 6.0. Preferably, the pH of the formulation is maintained in the range of approximately 3.5 to 5.0 or 3.5 to 5.5, most preferably from 3.7 to 4.3 or 3.8 to 4.2. An especially preferred pH is 4.0. It presently understood that where the pH of the pharmaceutical formulation exceeds 5.5, chemical degradation of the peptide may be accelerated such that the shelf life is less than about two years.

The buffer used in the practice of the present invention is an acetate buffer (preferably at a final formulation concentration of from about 1-5 to about 60 mM), phosphate buffer (preferably at a final formulation concentration of from about 1-5 to about to about 30 mM) or glutamate buffer (preferably at a final formulation concentration of from about 1-5 to about to about 60 mM). The most preferred buffer is acetate (preferably at a final formulation concentration of from about 5 to about 30 mM).
A stabilizer may be included in the present formulation but, and importantly, is not needed. If included, however, a stabilizer useful in the practice of the present invention is a carbohydrate or a polyhydric alcohol. The present inventors have discovered that a suitable stabilizer useful in the practice of the present invention is approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol. The polyhydric alcohols and carbohydrates share the same feature in their backbones, i.e., -CHOH-CHOH-, which is responsible for stabilizing the proteins. The polyhydric alcohols include such compounds as sorbitol, mannitol, glycerol, and polyethylene glycols (PEGs). These compounds are straight-chain molecules. The carbohydrates, such as mannose, ribose, trehalose, maltose, inositol, and lactose, on the other hand, are cyclic molecules that may contain a keto or aldehyde group. These two classes of compounds have been demonstrated to be effective in stabilizing protein against denaturation caused by elevated temperature and by freeze-thaw or freeze-drying processes. Suitable carbohydrates include: galactose, arabinose, lactose or any other carbohydrate which does not have an adverse affect on a diabetic patient, i.e., the carbohydrate is
not metabolized to form large concentrations of glucose in the blood. Such carbohydrates are well known in the art as suitable for diabetics.

Preferably, if a stabilizer is included, the peptide of the present invention is stabilized with a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various polyethylene glycols (PEG) of molecular weight 200, 400, 1450, 3350, 4000, 6000, and 8000). Mannitol is the preferred polyhydric alcohol. Another useful feature of the lyophilized formulations of the present invention is the maintenance of the tonicity of the lyophilized formulations described herein with the same formulation component that serves to maintain their stability. Mannitol is the preferred polyhydric alcohol used for this purpose.

The United States Pharmacopeia (USP) states that anti-microbial agents in bacteriostatic or fungistatic concentrations must be added to preparations contained in multiple dose containers. They must be present in adequate concentration at the time of use to prevent the multiplication of microorganisms inadvertently introduced into the preparation while withdrawing a portion of the contents with a hypodermic needle and
syringe, or using other invasive means for delivery, such as pen injectors. Antimicrobial agents should be evaluated to ensure compatibility with all other components of the formula, and their activity should be evaluated in the total formula to ensure that a particular agent that is effective in one formulation is not ineffective in another. It is not uncommon to find that a particular agent will be effective in one formulation but not effective in another formulation.

A preservative is, in the common pharmaceutical sense, a substance that prevents or inhibits microbial growth and may be added to pharmaceutical formulation for this purpose to avoid consequent spoilage of the formulation by microorganisms. While the amount of the preservative is not great, it may nevertheless effect the overall stability of the peptide. Thus, even selection of a preservative can be difficult.

While the preservative for use in the practice of the present invention can range from 0.005 to 1.0% (w/v), the preferred range for each preservative, alone or in combination with others, is: benzyl alcohol (0.1-1.0%), or m-cresol (0.1-0.6%), or phenol (0.1-0.8%) or combination of methyl (0.05-0.25%) and ethyl or propyl or butyl (0.005%-0.03%) parabens. The parabens are
lower alkyl esters of para-hydroxybenzoic acid.


Pramlintide (previously referred to as "AC-137") does not have a tendency to adsorb onto the glass in a glass container when in a liquid form, therefore, a surfactant is not required to further stabilize the pharmaceutical formulation. However, with regard to amylin agonists or amylin which do have such a tendency, a surfactant should be used in their formulation which formulations should then be lyophilized. Surfactants frequently cause denaturation of protein, both of hydrophobic disruption and by salt bridge separation. Relatively low concentrations of surfactant exert a potent denaturing activity, because of the strong interactions between surfactant moieties and the reactive sites on proteins. However, judicious use of this interaction can stabilize proteins against interfacial or surface denaturation. Surfactants which could further stabilize the peptide may optionally be present in the range of about 0.001 to 0.3% (w/v) of the total formulation and include polysorbate 80 (i.e.,
polyoxyethylene(20) sorbitan monooleate), CHAPS® (i.e., 3-[(3-cholamidopropyl)dimethylammonio]1-propanesulfonate), Brij® (e.g., Brij 35, which is (polyoxyethylene (23) lauryl ether), poloxamer, or another non-ionic surfactant.

It may also be desirable to add sodium chloride or other salt to adjust the tonicity of the pharmaceutical formulation, depending on the tonicifier selected. However, this is optional and depends on the particular formulation selected. Parenteral formulations must be isotonic or substantially isotonic otherwise significant irritation and pain would occur at the site of administration.

The vehicle of greatest importance for parenteral products is water. Water of suitable quality for parenteral administration must be prepared either by distillation or by reverse osmosis. Only by these means is it possible to separate adequately various liquid, gas and solid contaminating substances from water. Water for injection is the preferred aqueous vehicle for use in the pharmaceutical formulation of the present invention.

It is possible that other ingredients may be present in the peptide pharmaceutical formulation of the
present invention. Such additional ingredients may include wetting agents, emulsifiers, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatin or proteins) and a zwitterion (e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine). Such additional ingredients, of course, should not adversely affect the overall stability of the pharmaceutical formulation of the present invention.

Containers are also an integral part of the formulation of an injection and may be considered a component, for there is no container that is totally insoluble or does not in some way affect the liquid it contains, particularly if the liquid is aqueous. Therefore, the selection of a container for a particular injection must be based on a consideration of the composition of the container, as well as of the solution, and the treatment to which it will be subjected. Adsorption of the peptide to the glass surface of the vial can also be minimized, if necessary, by use of borosilicate glass, for example, Wheaton Type I borosilicate glass #33 (Wheaton Type I-33) or its equivalent (Wheaton Glass Co.). Other vendors of
similar borosilicate glass vials and cartridges acceptable for clinical manufacture include Kimbel Glass Co., West Co., Bünder Glas GMBH and Forma Vitrum. The biological and chemical properties of amylin may be stabilized by formulation and lyophilization in a Wheaton Type I-33 borosilicate serum vial to a final concentration of 1.0 mg/ml and 10 mg/ml of amylin in the presence of 5% mannitol, and 0.02% Tween 80.

In order to permit introduction of a needle from a hypodermic syringe into a multiple-dose vial and provide for resealing as soon as the needle is withdrawn, each vial is sealed with a rubber closure held in place by an aluminum band.

Stoppers for glass vials, such as, West 4416/50, 4416/50 (Teflon faced) and 4406/40, Abbott 5139 or any equivalent stopper can be used as the closure for pharmaceutical for injection. These stoppers are compatible with the peptide as well as the other components of the formulation. The inventors have also discovered that these stoppers pass the stopper integrity test when tested using patient use patterns, e.g., the stopper can withstand at least about 100 injections.

Each of the components of the pharmaceutical
formulation described above is known in the art and is
described in *Pharmaceutical Dosage Forms: Parenteral
Dekker, New York, N.Y. 1992, which is incorporated by
reference in its entirety herein.

The manufacturing process for the above formulation
involves compounding, sterile filtration and filling
steps. The compounding procedure involves dissolution
of ingredients in a specific order (preservative
followed by stabilizer/tonicity agents, buffers and
pramlintide) or dissolving at the same time.

Any sterilization process can be used in developing
the peptide pharmaceutical formulation of the present
invention. Typical sterilization processes include
filtration, steam (moist heat), dry heat, gases (e.g.,
ethylene oxide, formaldehyde, chlorine dioxide,
propylene oxide, beta-propiolactone, ozone,
chloropicrin, peracetic acid methyl bromide and the
like), radiant exposure and aseptic handling.

Filtration is the preferred method of sterilization in
the practice of the present invention. The sterile
filtration involves filtration through 0.45 μm and 0.22
μm (1 or 2) connected in a series. After filtration,
the solution is filled into appropriate vials as
described above.

The pharmaceutical formulation of the present invention is intended for parenteral administration. Suitable routes of administration include intramuscular, intravenous, subcutaneous, intradermal, intraarticular, intrathecal and the like. The subcutaneous route of administration is preferred. Mucosal delivery is also permissible.

The formulations of the present invention are especially advantageous because they retain short term mixing compatibility with insulin. Currently, there are over thirty insulin products available in the United States. All regular insulin preparations in the United States are now supplied at neutral pH. This has resulted in improved stability of the hormone, and patients need no longer refrigerate the vial of insulin in use. Furthermore, neutral regular insulin can be mixed in any desired proportion with other, modified insulin preparations since all marketed insulin preparations will be at the same pH. Preparations of insulin have been divided into three general categories according to promptness, duration, and intensity of action following subcutaneous administration. They are classified as fast-, intermediate-, and long-acting
insulins. There are also various types of insulins within these categories. They include regular insulins, protamine zinc insulins, NPH insulins, semilente insulins (prompt insulin zinc suspensions), lente insulins (insulin zinc suspensions), and ultralente insulins (extended insulin zinc suspensions).

Crystalline insulin is prepared by the precipitation of the hormone in the presence of zinc (as zinc chloride) in a suitable buffer medium. Crystalline insulin when dissolved in water is also known as regular insulin. Following subcutaneous injection it is rapidly absorbed (15-60 minutes). Its action is prompt in onset and relatively short in duration, i.e., it reaches its peak effect in about 1.5 to 4 hours, and lasts for about 5-9 hours.

By permitting insulin and zinc to react with the basic protein protamine, Hagedorn and associates prepared a protein complex, protamine zinc insulin. When this complex is injected subcutaneously in an aqueous suspension, it dissolves only slowly at the site of deposition, and the insulin is absorbed at a retarded but steady rate. Protamine zinc suspension insulin has largely been replaced by isophane insulin suspension, also known as NPH insulin; the N denotes a neutral
solution (pH 7.2), the P refers to the protamine zinc insulin content, and the H signifies the origin in Hagedorn’s laboratory. It is a modified protamine zinc insulin suspension that is crystalline. The concentrations of insulin, protamine, and zinc are so arranged that the preparation has an onset and a duration of action intermediate between those of regular insulin and protamine zinc insulin suspension. Its effects on blood sugar are indistinguishable from those of an extemporaneous mixture of 2 to 3 units of regular insulin and 1 unit of protamine zinc insulin suspension.

Chemical studies have revealed that the solubility of insulin is determined in important measure by its physical state (amorphous, crystalline, size of the crystals) and by the zinc content and the nature of the buffer in which it is suspended. Insulin can thus be prepared in a slowly absorbed, slow-acting form without the use of other proteins, such as protamine, to bind it. Large crystals of insulin with high zinc content, when collected and resuspended in a solution of sodium acetate-sodium chloride (pH 7.2 to 7.5), are slowly absorbed after subcutaneous injection and exert an action of long duration. This crystal preparation is named extended insulin zinc suspension (ultralente
insulin). Amorphous insulin precipitated at high pH is almost as rapid in onset as regular insulin, but has a somewhat longer duration of action. This amorphous preparation is named prompt insulin zinc suspension (semilente insulin). These two forms of insulin may be mixed to yield a stable mixture of crystalline (7 parts) and amorphous (3 parts) insulin - called insulin zinc suspension (lente insulin) -- that is intermediate in onset and duration of action between semilente and ultralente preparations and is similar to NPH insulin.

In summary, the fast-acting insulins include the regular insulins and the prompt insulin zinc suspensions (semilente insulins). The intermediate-acting insulins include the isophane insulin suspensions (NPH insulins, isophane insulin) and the insulin zinc suspensions (lente insulins). The long-acting insulins include protamine zinc insulin suspensions, and extended insulin zinc suspensions (ultralente insulins). Most of these preparations are available as either porcine or bovine insulins. Human insulins of recombinant DNA origin are available as regular and isophane insulins and as insulin zinc suspensions. Recently, a modified insulin (Lys(B28), Pro(B29) human insulin analog, created by reversing the amino acids at positions 28 and 29 on the
insulin B-chain) has been introduced. It is a fast-acting insulin, with a more rapid onset of glucose lowering action, an earlier peak action, and a shorter duration of action than regular human insulin.

Many insulins are available from a number of companies. These include Eli Lilly & Company and Novo Nordisk, two of the largest suppliers of insulin in the world. Fast-acting insulins available from Eli Lilly include (1) Iletin® I (Regular); (2) Regular Iletin® II (Pork, 100 Units); (3) Regular Iletin® II (Concentrated, Pork, 500 Units); (4) Humalog® Injection (insulin lyspro, recombinant DNA origin); and (5) Humulin® R (regular insulin, recombinant DNA origin, 100 Units). Fast-acting insulins available from Novo Nordisk include (1) Novolin® R (Regular, Human Insulin Injection (recombinant DNA origin) 100 Units); (2) Novolin® R PenFill 1.5 ml Cartridges (Regular, Human Insulin Injection (recombinant DNA origin) 100 Units); (3) Novolin® R Prefilled™ (Regular, Human Insulin Injection (recombinant DNA origin) in a 1.5 ml Prefilled Syringe, 100 units/ml); (4) Regular Purified Pork Insulin (100 Units/ml); and (5) Velosulin® BR (Buffered Regular Human Insulin Injection, 100 Units/ml). Intermediate-acting insulins available from Eli Lilly include (1) Humulin®
50/50 (50% human insulin isophane suspension and 50% human insulin injection (rDNA origin), 100 Units); (2) Humulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection (rDNA origin), 100 Units); (3) Humulin® L (lente; human insulin (rDNA origin) zinc suspension, 100 Units); (4) Humulin® N (NPH; human insulin (rDNA origin) isophane suspension, 100 Units); (5) Lente® Iletin® I, (insulin zinc suspension, beef-pork); (6) NPH Iletin® I (isophane insulin suspension, beef-pork); (7) Lente Iletin® II NPH (insulin zinc suspension, purified pork); and (8) NPH Iletin® II, (isophane insulin suspension, purified pork).

Intermediate-acting insulins available from Novo Nordisk include (1) Novolin® L (Lente, Human Insulin Zinc Suspension (recombinant DNA origin), 100 Units/ml); (2) Novolin® N (NPH, Human Insulin Isophane Suspension (recombinant DNA origin), 100 Units/ml); (3) Novolin® N PenFill® 1.5 ml Cartridges; (4) Novolin® N Prefilled® (NPH, Human Insulin Isophane Suspension (recombinant DNA origin) in a 1.5 ml Prefilled Syringe, 100 Units/ml); (5) Novolin® 70/30 (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin), 100 Units/ml); (6) Novolin® 70/30 PenFill® 1.5 ml Cartridges; (7) Novolin® 70/30
Prefilled™ (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin) in a 1.5 ml Prefilled Syringe, 100 Units/ml); (8) Lente Purified Pork Insulin (Zinc Suspension, USP 100 Units/ml); and (9) NPH Purified Pork Isophane Insulin Suspension (100 Units/ml). Long acting insulins include Eli Lilly’s Humulin® U (Ultrasente® human insulin (recombinant DNA origin) extended zinc suspension).

This invention provides unique peptide formulations, preferably pramlintide peptide formulations, which facilitate the short-term mixing compatibility of all types of insulin products including regular insulin products (e.g., Humulin® R and Novolin® R), intermediate-acting insulin products (e.g., Humulin® 70/30 and Novolin® 70/30) and long-acting insulin products (e.g., Humulin® U) with the peptide formulation before injection. The desired bioavailability of insulin and amylin agonist peptide or amylin is maintained. This results in a significant reduction in the number of injections per day in patients who are undergoing treatment with insulin and an amylin agonist (e.g., pramlintide) or amylin.

Insulin as well as insulin analogs are useful in
the practice of the present invention. Monomeric insulin analogs have been developed, e.g., Lys$^8$Pro$^{29}$-human insulin, which is also referred to as "LysPro insulin" or "insulin lispro." These analogs are said to be advantageous because they can be stabilized by ligands which induce the otherwise monomeric analog to associate under pharmaceutically useful conditions. This stabilized analog remains fast acting in an associated state.

Thus, any type of insulin may be drawn into a syringe along with the peptide formulation of the present invention. Any order of mixing or introduction of peptide and insulin into a syringe is also possible, but the preferred order is to place the insulin in the syringe first, followed by peptide in order to reduce the potential for cross-contamination and precipitation.

The amount of insulin and peptide formulation in the syringe depends on the individual needs of a particular patient. Accordingly, the amount present in a syringe is an amount sufficient to maintain a proper insulin level for a patient. The pharmaceutical formulations of the present invention can be administered to any human or mammal in need of such treatment.
As has been demonstrated with pramlintide, and depending upon the type of insulin and the volume ratio of the mixture, the insulin and peptide formulation can remain in the same syringe for at least about 24 hours and the insulin and the peptide will retain their activity and stability.

For instance, regular insulin products can be mixed with a peptide, e.g., pramlintide, at a pH of approximately 4.0 with 20 or 30 mM acetate buffer to maintain the solubility of the insulin. The pH of the mixture would then be less than 4.5. A preferred peptide formulation of pramlintide with a higher buffer capacity (30 mM acetate) and at low label strength, e.g., 0.1 mg/ml, forms a clear solution instantaneously (under a minute) when mixed with regular insulin products in the range of five to 20 units. This low label strength of pramlintide results in a high dose volume, 300 μL. This increased volume may be advantageous for bringing the pH down to less than 4.5 almost immediately by increasing insulin dilution factor and facilitating the transition of insulin from hexamer to monomer before injection. This modulation of insulin is believed to be advantageous in permitting increased rate of absorption and causing rapid-time action without
affecting bioavailability of insulin. This effect may approach the rapid-time action observed in Lys^{28}Pro^{29} human insulin.

Peptide formulations, e.g., pramlintide, at a pH from 4.0 to 5.5, 2 to 30 mM buffer concentration and high potency, can be mixed with regular insulin products before injection to yield solutions with a pH greater than 6.8 so that the properties of insulin are not affected. These mixtures would not affect the rate of absorption or bioavailability of insulin nor the bioavailability of the peptide.

Formulations of the invention are generally described above. Below are provided examples of various formulations useful in the invention. These examples are not limiting to the invention and those of ordinary skill in the art can readily construct other formulations within the ambit of the claims.

The invention will now be described in greater detail by reference to the following non-limiting examples.

**Example 1**

**LIQUID PRAMLINTIDE FORMULATION**

This example describes two preferred liquid formulations for pramlintide. Major degradation
pathways for the peptide are deamination and peptide bond hydrolysis. Therefore, the stability of the peptide was investigated in the pH region of 4.0 - 5.5 at 45°C. The pH-rate profile for the peptide in 60 mM acetate buffer, 4.1% mannitol, 0.3% m-cresol is shown in Figure 1. It can be observed from this figure that Pro^{25, 28, 29} h-amylin over the pH range studied is most stable at pH 4.0. The following formulation was developed:

**TABLE A**

<table>
<thead>
<tr>
<th>INGREDIENT</th>
<th>Weight (%)/Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramlintide</td>
<td>0.01-0.2</td>
</tr>
<tr>
<td>Acetate (30 mM, pH 4.0±0.1):</td>
<td></td>
</tr>
<tr>
<td>sodium acetate trihydrate</td>
<td>0.061</td>
</tr>
<tr>
<td>glacial acetic acid</td>
<td>0.153</td>
</tr>
<tr>
<td>mannitol</td>
<td>4.3</td>
</tr>
<tr>
<td>m-cresol</td>
<td>0.225</td>
</tr>
<tr>
<td>Water For Injection (qs)</td>
<td>100 mL</td>
</tr>
</tbody>
</table>

The above formulation with 0.01% drug showed an acceptably low irritancy in rabbit subcutaneous irritancy study. The placebo of this formulation when tested in humans also showed an acceptably high level of tolerability and low irritancy. The preservative used in the formulation meets BP criteria for preservative
efficacy at m-cresol levels as low as 0.15%.

The stability of the above formulation with 0.01% peptide was evaluated at 4°C and accelerated conditions, 30°C, 40°C and 50°C. Based on strong cation exchange and HPLC analysis for purity and potency, semi-logarithmic plots of % Initial purity or potency versus time for the peptide were constructed as shown in Figures 2, 3 and 4. It can be observed from this plot that the degradation of the peptide follows first order kinetics and that the degradation rate (represented by slopes of these plots), increases significantly with an increase in temperature.

Figure 5 shows plot of ln($k_{obs}$) versus 1/Temperature, constructed based on the Arrhenius relationship. It can be observed from this plot that the degradation of pramlintide in the formulation follows Arrhenius kinetics. By extrapolation of the plot to 5°C rate constant was calculated and shelf-life of up to four years for the peptide was predicted using this rate constant. Approximately 10% loss of potency and/or 5% to 7% degradation was considered acceptable. The shelf-life of the pharmaceutical formulation at 30°C based on direct measurement is at least 60 days.
Example 2

LIQUID PRAMLINTIDE FORMULATION

Table B describes second the peptide formulation with a shelf-life of greater than 4 years at 4°C and greater than 60 days at 30°C. This formulation differs from the one in Table A in acetate buffer concentration. This formulation also showed no irritancy in a rabbit subcutaneous irritancy study. Additionally, the placebo did not show significant irritancy in humans. The shelf-lives of this formulation are at least as great as the formulation given in Table A, both formulations being novel parenteral peptide dosage forms with substantial shelf-lives.

<table>
<thead>
<tr>
<th>INGREDIENT</th>
<th>Weight (%)/Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramlintide</td>
<td>0.01 - 0.2</td>
</tr>
<tr>
<td>Acetate (20 mM, pH 4.0±0.1):</td>
<td></td>
</tr>
<tr>
<td>sodium acetate trihydrate</td>
<td>0.049</td>
</tr>
<tr>
<td>glacial acetic acid</td>
<td>0.0985</td>
</tr>
<tr>
<td>mannitol</td>
<td>4.3</td>
</tr>
<tr>
<td>m-cresol</td>
<td>0.225</td>
</tr>
<tr>
<td>Water for injection (gs)</td>
<td>100 mL</td>
</tr>
</tbody>
</table>
Example 3

LIQUID PRAMLINTIDE FORMULATION AND INSULIN

The formulations reported in Tables A and B are also compatible when mixed in a syringe with commercially available insulin products. Table C provides results of insulin compatibility study with Humulin® R. The results indicate the time to form a clear solution and criteria for compatibility, when the peptide formulation is mixed with Humulin R in a specific ratio in a syringe. As outlined by Brange et al, "Insulin Structure and Stability," in Stability and Characterization of Protein and Peptide Drugs: Case Histories, 1993, Wang et al. (Ed), Plenum Press, NY, insulin has an isoelectric precipitation zone pH range of 4.5 - 6.5, within 1 pH unit from isoelectric point. Therefore, if the pH of the insulin product drops from 7.2 ± 0.2 to pH in the isoelectric precipitation range it may cause insulin to precipitate. Thus, clarity of the solution mixture was used as a criteria for compatibility studies. The insulin volumes used in this study (Table C) cover the maximum and minimum ranges typical for Type I diabetic patients. The formulation with higher buffer capacity (Table C) forms a clear solution faster than the lower buffer capacity.
formulation. However, at 0.01% of the peptide label strength both formulations form a clear solution with insulin within approximately one minute. In a syringe, one minute can be considered to be instantaneous mixing. The higher label strengths of the peptide (0.015% or higher) results in lower dose volume and causes longer than a minute to form a clear solution. The final pH of all solution mixtures fall outside of insulin isoelectric precipitation range (pH 4.5 - 6.5).
### TABLE C

<table>
<thead>
<tr>
<th>Pramlintide Formulation Variants</th>
<th>Insulin: Pramlintide Mixing Volume Ratio (µL:µL)</th>
<th>pH of the Mixture</th>
<th>Time to Form Clear Solution (sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Label Strength (%)</strong></td>
<td><strong>Acetate (mM)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01</td>
<td>30</td>
<td>4.03</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>50 (5 units):300</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>150:300</td>
<td>4.10</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>200:300</td>
<td>4.13</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>4.09</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>50:300</td>
<td>4.15</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>150:300</td>
<td>4.20</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>200:300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.015</td>
<td>30</td>
<td>4.05</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>50:200</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>150:200</td>
<td>4.12</td>
<td>99</td>
</tr>
<tr>
<td></td>
<td>200:200</td>
<td>4.24</td>
<td>192</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>4.13</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>50:200</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>150:200</td>
<td>4.27</td>
<td>197</td>
</tr>
<tr>
<td></td>
<td>200:200</td>
<td>4.30</td>
<td>300</td>
</tr>
</tbody>
</table>

The formulation with 0.03% label strength (Table A) was subjected to in vivo compatibility study in rats. Figure 6 shows the plasma concentration versus time for insulin. The study indicated no significant differences in the bioavailability of either insulin or peptide when
injected together after mixing or separately as individual injections. Therefore, these novel formulations are not only stable but also compatible with regular insulin products such as, Humulin® R and Novolin® R.

The preferred formulations (Tables A and B) were also tested for compatibility with intermediate acting (Humulin® 70/30) and long acting (Humulin® N) insulin products. These two insulin products are suspensions and they both contain soluble and insoluble insulin portions in specific ratios, and these ratios are required to achieve targeted bioavailability. Therefore, when mixed with the peptide formulation the ratio of soluble to insoluble insulin should be maintained. The sample preparation to separate soluble to insoluble portions from peptide/insulin mixtures was adopted from Arakawa et al., Diabetes Research and Clinical Practice, 1989. Samples were analyzed using a reverse phase HPLC assay. Table D summarizes the results of the study. Both formulations maintain the soluble to insoluble ratios as in control formulations when Humulin® 70/30 and Pro²⁵,²⁸,²⁹ h-amylin formulations are mixed in a 3:1 ratio. Therefore, in a preferred formulation the dose volume should be maintained by
choosing an appropriate peptide label strength. For example, using 0.6 mg/mL or 0.06% label strength formulation to mix with 15 units of Humulin 70/30.

**TABLE D**

<table>
<thead>
<tr>
<th>Pramlintide Formulation Variants (Label Strength: 0.3 mg/mL or 0.03%)</th>
<th>Insulin: Pramlintide Ratio (μL:μL)</th>
<th>pH of the Mixture</th>
<th>Percent Soluble Insulin</th>
<th>% Soluble Pramlintide</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>Acetate (mM)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.0</td>
<td>20</td>
<td>6.77</td>
<td>12</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>300:30 Units:100</td>
<td>5.74</td>
<td>4</td>
<td>100</td>
</tr>
<tr>
<td>4.0</td>
<td>30</td>
<td>6.41</td>
<td>10</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>300:100:100</td>
<td>5.15</td>
<td>4</td>
<td>98</td>
</tr>
<tr>
<td>Humulin N:Humulin R (70:30) (control)</td>
<td>N/A</td>
<td>7.12</td>
<td>11</td>
<td>N/A</td>
</tr>
<tr>
<td>Premixed Humulin 70/30 (control)</td>
<td>100:0</td>
<td>7.46</td>
<td>16</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Table E shows compatibility data for formulations with long acting insulin product, Humulin® N. The Humulin® N covers a normal dosage range for Type I diabetic patients. The soluble to insoluble ratios do not change significantly compared to the control when preferred formulations, in Tables A and B, are mixed with Humulin® N. The preferred peptide dose volume is
100 μL.

The formulations described in Tables A and B of Example 1 are preferred formulations with necessary stability and insulin compatibility requirements.

**TABLE E**

<table>
<thead>
<tr>
<th>Pramlintide Formulation Variants (Label Strength: 0.3 mg/mL or 0.03%)</th>
<th>Insulin: Pramlintide Ratio (μL:μL)</th>
<th>pH of the Mixture</th>
<th>Percent Soluble Insulin</th>
<th>% Soluble Pramlintide</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>Acetate (mM)</td>
<td>160 (16 Units):100</td>
<td>5.51</td>
<td>2</td>
</tr>
<tr>
<td>4.0</td>
<td>20</td>
<td>120:100</td>
<td>5.10</td>
<td>4</td>
</tr>
<tr>
<td>4.0</td>
<td>30</td>
<td>160:100</td>
<td>5.06</td>
<td>3</td>
</tr>
<tr>
<td>120:100</td>
<td>4.82</td>
<td>4</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>Humulin (control)</td>
<td>N:100:0</td>
<td>7.20</td>
<td>2</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Example 4**

**LIQUID PEPTIDE FORMULATION AND INSULIN**

The formulation in this example is the preferred formulation for mixing with intermediate acting (Humulin® 70/30 & Novolin® 70/30) and long acting (Humulin® N and Novolin® N) insulin products.
TABLE F

<table>
<thead>
<tr>
<th>INGREDIENT</th>
<th>Weight (%)/Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramlintide</td>
<td>0.03</td>
</tr>
<tr>
<td>Acetate (12 mM, pH 4.4)</td>
<td></td>
</tr>
<tr>
<td>sodium acetate trihydrate</td>
<td>0.0555</td>
</tr>
<tr>
<td>glacial acetic acid</td>
<td>0.0476</td>
</tr>
<tr>
<td>mannitol</td>
<td>4.4</td>
</tr>
<tr>
<td>m-cresol</td>
<td>0.225</td>
</tr>
<tr>
<td>Water for injection (qs)</td>
<td>100 mL</td>
</tr>
</tbody>
</table>

The stability of this formulation is 3.3 years at 5°C, calculated by extrapolation using accelerated stability data, and found to be 33 days at 30°C using the real time data. The insulin compatibility studies with Humulin® 70/30 and Humulin® N were conducted following the procedure outlined in Example 3. The formulation maintains insulin soluble to insoluble ratios in the range of controls when mixed with Humulin® 70/30 (Table G) or Humulin® N (Table H). The pH of the mixture does not deviate from the control samples.
TABLE G

<table>
<thead>
<tr>
<th>Pramlintide Formulation Variants (Label Strength: 0.3 mg/mL or 0.03%)</th>
<th>Insulin: Pramlintide Ratio (µL:µL)</th>
<th>pH of the Mixture</th>
<th>Percent Soluble Insulin</th>
<th>% Soluble Pramlintide</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>Acetate (mM)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.4</td>
<td>12</td>
<td>300:100</td>
<td>7.02</td>
<td>13</td>
</tr>
<tr>
<td>150:100</td>
<td>6.82</td>
<td>11</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>Humulin® N:Humulin® R (70:30) (Control)</td>
<td>N/A</td>
<td>7.12</td>
<td>11</td>
<td>N/A</td>
</tr>
<tr>
<td>Premixed Humulin® 70/30 (Control)</td>
<td>100:0</td>
<td>7.46</td>
<td>16</td>
<td>N/A</td>
</tr>
</tbody>
</table>

TABLE H

<table>
<thead>
<tr>
<th>Pramlintide Formulation Variants (Label Strength: 0.3 mg/mL or 0.03%)</th>
<th>Insulin: Pramlintide Ratio (µL:µL)</th>
<th>pH of the Mixture</th>
<th>Percent Soluble Insulin</th>
<th>% Soluble Pramlintide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph</td>
<td>Acetate (mM)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.4</td>
<td>12</td>
<td>160:100</td>
<td>6.54</td>
<td>3</td>
</tr>
<tr>
<td>120:100</td>
<td>6.26</td>
<td>1</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>Humulin® (Control)</td>
<td>N100:0</td>
<td>7.20</td>
<td>2</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Example 5

LIQUID PRAMLIINTIDE FORMULATION

This is a formulation with low buffer concentration, 10 mM of acetate buffer and pH closer to 53.
physiological pH compared to the formulations in examples 1-4. The stability of this formulation is calculated by extrapolation to be 2.76 years 5°C based on accelerated stability data and found to be 32 days at 30°C using real time data.

**TABLE I**

<table>
<thead>
<tr>
<th>INGREDIENT</th>
<th>Weight (%) / Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramlintide</td>
<td>0.01 - 0.4</td>
</tr>
<tr>
<td>Acetate (10 mM, pH 4.7)</td>
<td></td>
</tr>
<tr>
<td>sodium acetate trihydrate</td>
<td>0.066</td>
</tr>
<tr>
<td>glacial acetic acid</td>
<td>0.0309</td>
</tr>
<tr>
<td>mannitol</td>
<td>4.5</td>
</tr>
<tr>
<td>m-cresol</td>
<td>0.225 - 0.3</td>
</tr>
<tr>
<td>Water for injection (qs)</td>
<td>100 mL</td>
</tr>
</tbody>
</table>

**Example 6**

**LYOPHILIZED PEPTIDE FORMULATION**

Amylin agonists may be stabilized by lyophilization of the formulation listed in Table J. This formulation is intended for amylin agonists or amylinns having physicochemical characteristics that include lower solubility and/or higher instability.

Pramlintide, however, a superior amylin agonist peptide, may also be lyophilized in the formulation listed in Table J.
**TABLE J**

<table>
<thead>
<tr>
<th>INGREDIENT</th>
<th>WEIGHT (%) / RANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amylin Agonist</td>
<td>0.03-1.0</td>
</tr>
<tr>
<td>Mannitol</td>
<td>5.0</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>0.02</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>100 ml</td>
</tr>
<tr>
<td>(qs)</td>
<td></td>
</tr>
</tbody>
</table>

**Example 7**

**LIQUID PEPTIDE FORMULATION**

Amylin agonists such as pramlintide may be minimally formulated with 30mM acetate buffer as described in Table K

**TABLE K**

<table>
<thead>
<tr>
<th>INGREDIENT</th>
<th>WEIGHT (%) / RANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramlintide</td>
<td>0.01-0.5</td>
</tr>
<tr>
<td>Glacial Acetic Acid</td>
<td>0.153</td>
</tr>
<tr>
<td>Sodium Acetate Trihydrate</td>
<td>0.061</td>
</tr>
</tbody>
</table>
WE CLAIM:

1. A liquid, pharmaceutical formulation comprising about 0.01 to about 0.5% (w/v) of an amylin agonist, about 1.0 to about 10% (w/v) of a carbohydrate or a polyhydric alcohol, and about 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer, and which has a pH about 3.0 to about 6.0.

2. The liquid, pharmaceutical formulation of claim 1 which is substantially isotonic.

3. The liquid, pharmaceutical formulation of claim 1 which further comprises a preservative.

4. The liquid, pharmaceutical formulation of claim 3 wherein said preservative is selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol.

5. The liquid, pharmaceutical formulation of any of claims 1-4, wherein said amylin agonist is pramlintide.

6. The liquid, pharmaceutical formulation of any of claims 1-4, wherein said polyhydric alcohol is selected from the group consisting of mannitol, sorbitol, inositol, glycerol, xylitol, propylene/ethylene glycol copolymer, PEG 8000, PEG 400, PEG 4000, PEG 200, PEG 1450 or PEG 3350.
7. The liquid, pharmaceutical formulation of any of claims 1-4, wherein said polyhydric alcohol is mannitol.

8. The liquid, pharmaceutical formulation of any of claims 1-4, wherein said carbohydrate is selected from the group consisting of mannose, ribose, trehalose, maltose, glycerol, inositol and lactose.

9. The liquid, pharmaceutical formulation of any of claims 1-4, wherein said buffer is an acetate buffer.

10. The liquid, pharmaceutical formulation of any of claims 1-4, wherein the pH of said formulation is about 3.5 to about 5.0.

11. The liquid, pharmaceutical formulation of any of claims 1-4, wherein the pH of said formulation is about 3.8 to about 4.2.

12. The liquid, pharmaceutical formulation of any of claims 1-4, wherein said preservative is approximately at least about 0.15% (w/v) of m-cresol.

13. The liquid, pharmaceutical formulation of any of claims 1-4, wherein said preservative is approximately about 0.1 to about 0.3 (w/v) of m-cresol.

14. The liquid, pharmaceutical formulation of any of claims 1-4, wherein said formulation further comprises a surfactant.
15. The liquid, pharmaceutical formulation of any of claims 1-4, wherein said surfactant is selected from the group consisting of polyoxyethylene (20) sorbitan monooleate, 3-[(3-cholamidopropyl) dimethylammonio] 1-propan sulfonate, polyoxyethylene (23) lauryl ether, poloxamer or a non-ionic surfactant.

16. A formulation comprising an amylin agonist which is biologically active, has a reduced tendency to form aggregates in water or at a pressure of greater than 2 psi compared to human amylin, and has a reduced tendency to precipitate in the presence of NaCl compared to human amylin, admixed with one or more compounds which reduce loss of activity of said amylin agonist, in an amylin specific receptor binding assay or bioactivity assay or HPLC assay compared to a composition consisting of said amylin agonist in phosphate-buffered saline or saline, said compounds comprising a tonicity agent and a buffer, said tonicity agent being provided in an amount between 0.01% and 10% and said formulation having a pH of about 3.0 to about 6.0.

17. The formulation of claim 14, further comprising a preservative

18. A method for treating a patient with pramlintide, and insulin, said method comprising
admixing a formulation of pramlintide with insulin and administering the mixture of said formulation and insulin to a patient in need of such treatment, wherein said formulation comprising a tonicifier, a buffer and a preservative, said tonicifier comprising approximately 1.0 to 10% (w/v) of a carbohydrate or a polyhydric alcohol, said buffer comprising approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer which allows a pH of the final formulation of approximately 3.0 to 6.0, and said preservative comprising a compound selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol, and wherein said pramlintide comprises about 0.01 to about 0.5% (w/v) of the formulation.

19. A commercial package containing a liquid pharmaceutical formulation containing pramlintide, for parenteral administration to a patient, said package comprising a borosilicate glass vial having an open end, a stopper intended for multiuse which is compatible with the amylin and/or amylin agonist, fixed in the open end of the vial, an aluminum band to retain the stopper in the far end of the vial wherein said liquid pharmaceutical formulation comprises a tonicifier, a
buffer and a preservative, said tonicifier comprising 1.0 approximately to 10% (w/v) of a carbohydrate or a polyhydric alcohol, said buffer comprising approximately 0.02 to 0.5% (w/v) of an acetate, phosphate or glutamate buffer which allows a pH of the final formulation of approximately 3.0 to 6.0, and said preservative is selected from the group consisting of m-cresol, benzyl alcohol, methyl and ethyl parabens and phenol and said pramlintide approximately 0.01 to 0.5% (w/v) of the formulation.

20. A commercial package containing a liquid pharmaceutical formulation containing pramlintide, for parenteral administration to a patient, said package comprising a cartridge suitable for use in a pen injector wherein said liquid pharmaceutical formulation comprises a stabilizer, a buffer and a preservative, said stabilizer comprising 1.0 approximately to 10% (w/v) of a carbohydrate or a polyhydric alcohol, said buffer comprising approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer which allows a pH of the final formulation of approximately 3.0 to 6.0, and said preservative is selected from the group consisting of m-cresol, benzyl alcohol, methyl and ethyl parabens and phenol and said pramlintide is
approximately 0.01 to 0.5% (w/v) of the formulation.

21. A composition which comprises about 0.01 to about 0.5% (w/v) of pramlintide, about 1.0 to about 10% (w/v) of mannitol, and about 0.02 to about 0.5% (w/v) of an acetate buffer.

22. The composition of claim 21 which is a liquid.

23. The composition of claim 21 which further comprises about 0.1 to about 0.3% (w/v) of m-cresol.

24. The composition of claim 23 which is a liquid.

25. The composition of either of claims 22 or 24 which has a pH of from about 3.0 to about 6.0.

26. The composition of either of claims 22 or 24 which has a pH of from about 3.5 to about 5.0.

27. The composition of either of claims 22 or 24 which has a pH of from about 3.8 to about 4.2.

28. The composition of claim 21 which is lyophilized.

29. A composition which comprises about 0.01 to about 0.5% (w/v) of pramlintide and about 0.02 to about 0.5% (w/v) of an acetate buffer.

30. The composition of claim 29 which is a liquid.

31. The composition of claim 29 which is lyophilized.
FIG. 5.

$y = 10554x + 3.1$, max dev: 0.217, $r^2 = 0.977$

\[ f(x) = \ln(\frac{L}{N}) \]
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC(6) : A61K 38/28, 30/00; C07K 7/10
US CL : 514/3, 4, 12
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/3, 4, 12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS, CAS ONLINE, MEDLINE, EMBASE, BIOSIS, EPOABS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US 4,654,324 A (CHANCE et al.) 31 March 1987, see especially columns 3-4.</td>
<td>1-31</td>
</tr>
<tr>
<td>Y</td>
<td>WO 93/10146 (AMYLIN PHARMACEUTICALS, INC.) 27 May 1993, see entire document, especially pages 12-15, see entire document.</td>
<td>1-31</td>
</tr>
</tbody>
</table>

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

* Special categories of cited documents:
*A* document defining the general state of the art which is not considered to be of particular relevance
*E* earlier document published on or after the international filing date
*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
*D* document referring to an oral disclosure, use, exhibition or other means
*P* document published prior to the international filing date but later than the priority date claimed

Y later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A document member of the same patent family

Date of the actual completion of the international search 23 MARCH 1998
Date of mailing of the international search report 1 MAY 1998

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer of the ISA
BENNELL CELSA

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet), July 1992*
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>GENNARO, A.R. (ed.), Remington's Pharmaceutical Sciences 18th Ed. (Mack Publishing Co. 1990), pages 1545-1553, see entire article, especially pages 1547-1551.</td>
<td>1-31</td>
</tr>
</tbody>
</table>